Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cushing's Syndrome
- Sponsor
- Corcept Therapeutics
- Enrollment
- 24
- Primary Endpoint
- Drug Utilization Patterns as assessed by chart review
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome.
Detailed Description
A retrospective, multi-center, chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome. Treatment with Korlym® will be a minimum 3 months in duration with follow-up of a minimum 3 months. Only sites that have been identified to have patients appropriate for this protocol will be invited to participate.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosed with ACTH independent endogenous Cushing's Syndrome
- •Available adrenal imaging prior to being treated with Korlym®
- •Treated with Korlym® and followed for at least 3 months (follow-up data should be available)
Exclusion Criteria
- •Diagnosed with adrenocortical carcinoma
- •Participant in any clinical trial(s) during the observational period
Outcomes
Primary Outcomes
Drug Utilization Patterns as assessed by chart review
Time Frame: up to 4 years
The retrospective review would analyze the drug utilization patterns of patients treated with Korlym
Secondary Outcomes
- Clinical Outcomes as assessed by chart review(up to 4 years)